Preexisting human antibodies neutralize recently emerged H7N9 influenza strains

Journal of Clinical Investigation

Volumn 125, Issue 3, 2015, Pages 1255-1268

  Dunand, Carole J Henry ^a   Leon, Paul E ^b   Kaur, Kaval ^a,c   Tan, Gene S ^b   Zheng, Nai Ying ^a   Andrews, Sarah ^a   Huang, Min ^a   Qu, Xinyan ^a   Huang, Yunping ^a   Salgado Ferrer, Marlene ^a   Ho, Irvin Y ^a   Taylor, William ^a   Hai, Rong ^b   Wrammert, Jens ^d   Ahmed, Rafi ^d   García Sastre, Adolfo ^b   Palese, Peter ^b   Krammer, Florian ^b   Wilson, Patrick C ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; SIALIC ACID; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNITY; IN VITRO STUDY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N9; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CROSS REACTION; DOG; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H7N9); INFLUENZA, HUMAN; MDCK CELL LINE; PHYSIOLOGY; POINT MUTATION; SERODIAGNOSIS; VACCINATION; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DOGS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MICE, INBRED BALB C; NEUTRALIZATION TESTS; POINT MUTATION; VACCINATION;

EID: 84924034216     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74374     Document Type: Article

References (46)

1. Shaw ML Palese P. Orthomyxoviruses. In: Knipe DM, Howley PM, eds. Fields Virology. 6th ed. Philadelphia, Pennsylvania, USA: Lippincott Williams and Wilkins; 2013:1151-1185.
2. Kaur K, Sullivan M, Wilson PC. Targeting B cell responses in universal influenza vaccine design. Trends Immunol. 2011;32(11):524-531.
3. Air GM. Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. Proc Natl Acad Sci U S A. 1981;78(12):7639-7643.
4. Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol. 2011;9(8):590-603.
5. Hirst M, et al. Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis. 2004;10(12):2192-2195.
6. Fouchier RA, et al. Avia n influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101(5):1356-1361.
7. Gao R, et al. Human infec tion with a novel avianorigin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888-1897.
8. Belser JA, et al. Pathogenesis transmission of avian influenza A (H7N9) virus in ferrets mice. Nature. 2013;501(7468):556-559.
9. Watanabe T, et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 2013;501(7468):551-555.
10. M orens DM, Taubenberger JK, Fauci AS. H7N9 avian influenza A virus and the perpetual challenge of potential human pandemicity. MBio. 2013;4(4):1-14.
11. Hu Y,et al Association between adve rse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance Lancet. 2013 381 9885, 2273-2279.
12. Zhang Q, et al. H7N 9 influenza viruses are transmissible in ferrets by respiratory droplet. Science. 2013;341(6144):410-414.
13. Xu R, et al. Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science. 2013;342(6163):1230-1235.
14. Ramos I, et al. H7N9 influenza viruses interact preferentially with ?2,3-linked sialic acids and bind weakly to ?2,6-linked sialic acids. J Gen Virol. 2013;94(pt 11):2417-2423.
15. Hai R, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun. 2013;4:2854.
16. Wrammert J, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208(1):181-193.
17. Wrammert J, et al. Rapid cloning of high-Affinity human monoclonal antibodies against influenza virus. Nature. 2008;453(7195):667-671.
18. Krammer F, et al. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol. 2014;21(8):1153-1163.
19. Dreyfus C, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012;337(6100):1343-1348.
20. Kapczynski DR, et al. Characterization o f the 2012 highly pathogenic avian influenza H7N3 virus isolated from poultry in an outbreak in Mexico: pathobiology and vaccine protection. J Virol. 2013;87(16):9086-9096.
21. Brandenburg B, et al. Mec hanisms of hemagglutinin targeted influenza virus neutralization. PLoS One. 2013;8(12):e80034.
22. Tan GS, et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion d omain of group 2 influenza a virus hemagglutinin. J Virol. 2014;88(23):13580-13592.
23. Ekiert DC, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333(6044):843-850.
24. Hensley SE, et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science. 2009;326(5953):734-736.
25. Cor ti D, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest. 2010;120(5):1663-1673.
26. Li GM, et al. Pandemic H1N 1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A. 2012;109(23):9047-9052.
27. Thomson CA, et al. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front Immunol. 2012;3:87.
28. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. Nat Rev Immunol. 2012;12(10):709-719.
29. Ekiert DC, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature. 2012;489(7417):526-532.
30. Margine I, et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol. 2013;87(8):4728-4737.
31. Margine I, et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol. 2013;87(19):10435-10446.
32. Krammer F, et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol. 2014;88(4):2340-2343.
33. Ekiert DC, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324(5924):246-251.
34. Friesen RH, et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A. 2014;111(1):445-450.
35. O'Donnell CD, et al. Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice. MBio. 2012;3(3):e00120-12.
36. Wang TT, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010;6(2):e1000796.
37. Corti D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850-856.
38. Throsby M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One. 2008;3(12):e3942.
39. Sui J, et al. St ructural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009;16(3):265-273.
40. Krammer F, et al. Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol. 2014;88(8):3976-3985.
41. Margine I, Palese P, Krammer F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp. 2013;(81): e51112.
42. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods. 2004;286(1-2):111-122.
43. Quinlivan M, Zamarin D, Garcia-Sastre A, Cullinane A, Chambers T, Palese P. Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol. 2005;79(13) :8431-8439.
44. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol. 1999;73(11):9679-9682.
45. Hai R, et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol. 2012;86(10):5774-5781.
46. Smith K , et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4(3):372-384.